An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis

Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1–503. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: NICE; 2013. Rowen D, Zouraq IA, Chevrou-Severac H, van Hout B. International regulations and recommendations for utility data for health technology assessment. PharmacoEconomics. 2017;35(1):11–9. Hunter RM, Baio G, Butt T, Morris S, Round J, Freemantle N. An educational review of the statistical issues in analysing utility data for cost-utility analysis. PharmacoEconomics. 2015;33(4):355–66. Lloyd A. Special edition on utility measurement. PharmacoEconomics. 2017;35(Suppl 1):5–6. Akobeng A. Understanding randomised controlled trials. Arch Dis Child. 2005;90(8):840–4. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2014. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15(7):677–87. Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. PharmacoEconomics. 2008;26(9):799–806. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–50. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36):1–158. Ghabri S, Stevenson M, Möller J, Caro JJ. Trusting the results of model-based economic analyses: is there a pragmatic validation solution? PharmacoEconomics. 2019;37(1):1–6. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Mak. 2012;32(5):667–77. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Med Decis Mak. 2012;32(5):690–700. Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Möller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Med Decis Mak. 2012;32(5):701–11. Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task force-5. Value Health. 2012;15(6):828–34. Dolgin M, Fox AC. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. Brown Boston: Little; 1994. Briggs A, Gray A. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess. 1999;3(2):1–134. Walker S, Asaria M, Manca A, Palmer S, Gale CP, Shah AD, et al. Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER). Eur Heart J Qual Care Clin Outcomes. 2016;2(2):125–40. Last JM, Abramson JH, Freidman GD. A dictionary of epidemiology. New York: Oxford University Press; 2001. Deidda M, Geue C, Kreif N, Dundas R, McIntosh E. A framework for conducting economic evaluations alongside natural experiments. Soc Sci Med. 2019;220:353–61. Morton A, Adler AI, Bell D, Briggs A, Brouwer W, Claxton K, et al. Unrelated future costs and unrelated future benefits: reflections on NICE guide to the methods of technology appraisal. Health Econ. 2016;25(8):933–8. de Vries LM, van Baal PH, Brouwer WB. Future costs in cost-effectiveness analyses: past, present, future. PharmacoEconomics. 2018. https://doi.org/10.1007/s40273-018-0749-8. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103. Claxton K, Walker S, Palmer S, Sculpher M. CHE Research Paper 54: appropriate perspectives for health care decisions. York: University of York; 2010. Remme M, Martinez-Alvarez M, Vassall A. Cost-effectiveness thresholds in global health: taking a multisectoral perspective. Value Health. 2017;20(4):699–704. Culyer AJ. CHE Research Paper 154: cost, context and decisions in health economics and cost-effectiveness analysis. York: University of York; 2018. Ridyard CH, Hughes DA. Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program. Value Health. 2010;13(8):867–72. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editor. Measuring mental health needs. London: Gaskell; 2001. p. 200–24. Thorn JC, Coast J, Cohen D, Hollingworth W, Knapp M, Noble SM, et al. Resource-use measurement based on patient recall: issues and challenges for economic evaluation. Appl Health Econ Health Policy. 2013;11(3):155–61. Brazier J, Ara R, Rowen D, Chevrou-Severac H. A review of generic preference-based measures for use in cost-effectiveness models. PharmacoEconomics. 2017;35(1):21–31. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Medical Care. 1989;27(Suppl 3):S217–32. Longworth L, Yang Y, Young T, Mulhern B, Hernandez Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1–224. Rowen D, Brazier J, Ara R, Zouraq IA. The role of condition-specific preference-based measures in health technology assessment. PharmacoEconomics. 2017;35(1):33–41. Marti J, Hall PS, Hamilton P, Hulme CT, Jones H, Velikova G, et al. The economic burden of cancer in the UK: a study of survivors treated with curative intent. Psycho-Oncology. 2016;25(1):77–83. Thompson S, Wordsworth S. An annotated cost questionnaire for completion by patients. Aberdeen: Health Economics Research Unit, University of Aberdeen; 2001. Wimo A, Gustavsson A, Jönsson L, Winblad B, Hsu M-A, Gannon B. Application of Resource Utilization in Dementia (RUD) instrument in a global setting. Alzheimer’s Dementia. 2013;9(4):429–435.e17. Thorn JC, Brookes ST, Ridyard C, Riley R, Hughes DA, Wordsworth S, et al. Core Items for a Standardized Resource Use Measure (ISRUM): Expert Delphi Consensus Survey. Value Health. 2017;21(6):640–9. Ridyard CH, Hughes DA, Team D. Development of a database of instruments for resource-use measurement: purpose, feasibility, and design. Value Health. 2012;15(5):650–5. Franklin M, Berdunov V, Edmans J, Conroy S, Gladman J, Tanajewski L, et al. Identifying patient-level health and social care costs for older adults discharged from acute medical units in England. Age Ageing. 2014;43(5):703–7. Tanajewski L, Franklin M, Gkountouras G, Berdunov V, Edmans J, Conroy S, et al. Cost-effectiveness of a specialist geriatric medical intervention for frail older people discharged from acute medical units: economic evaluation in a two-centre randomised controlled trial (AMIGOS). PLoS One. 2015;10(5):e0121340. Tanajewski L, Franklin M, Gkountouras G, Berdunov V, Harwood RH, Goldberg SE, et al. Economic evaluation of a general hospital unit for older people with delirium and dementia (TEAM Randomised Controlled Trial). PLoS One. 2015;10(12):e0140662. NHS Digital. Hospital Episode Statistics (HES); 2018. https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics. Accessed 17 Oct 2018. McDonnell L, Delaney B, Sullivan F. Datasets that may be of interest to Primary Care Researchers in the UK; 2017. http://www.farrinstitute.org/wp-content/uploads/2017/10/Datasets-that-may-be-of-interest-to-Primary-Care-Researchers-in-the-UK-May-2016.pdf. Accessed 17 Oct 2018. Baker R, Tata LJ, Kendrick D, Orton E. Identification of incident poisoning, fracture and burn events using linked primary care, secondary care and mortality data from England: implications for research and surveillance. Inj Prev. 2015;22(1):59–67. Franklin M, Davis S, Horspool M, Kua WS, Julious S. Economic evaluations alongside efficient study designs using large observational datasets: the PLEASANT Trial Case Study. PharmacoEconomics. 2017;35(5):561–73. Herrett E, Shah AD, Boggon R, Denaxas S, Smeeth L, van Staa T, et al. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ. 2013;346:f2350. Asaria M, Grasic K, Walker S. Using linked electronic health records to estimate healthcare costs: key challenges and opportunities. PharmacoEconomics. 2016;34(2):155–60. Spencer SA, Davies MP. Hospital episode statistics: improving the quality and value of hospital data: a national internet e-survey of hospital consultants. BMJ Open. 2012;2(6):e001651. Thorn JC, Turner E, Hounsome L, Walsh E, Donovan JL, Verne J, et al. Validation of the hospital episode statistics outpatient dataset in England. PharmacoEconomics. 2016;34(2):161–8. Byford S, Leese M, Knapp M, Seivewright H, Cameron S, Jones V, et al. Comparison of alternative methods of collection of service use data for the economic evaluation of health care interventions. Health Econ. 2007;16(5):531–6. Noben CY, de Rijk A, Nijhuis F, Kottner J, Evers S. The exchangeability of self-reports and administrative health care resource use measurements: assessment of the methodological reporting quality. J Clin Epidemiol. 2016;74(93–106):e2. Franklin M, Thorn J. Self-reported and routinely collected electronic healthcare resource-use data for trial-based economic evaluations: the current state of play in England and considerations for the future. BMC Med Res Methodol. 2019;19(8):1–13. NHS Improvement. Reference costs; 2017. https://improvement.nhs.uk/resources/reference-costs/. Accessed 17 Oct 2018. PSSRU. Unit Costs of Health and Social Care; 2018. https://www.pssru.ac.uk/project-pages/unit-costs/. Accessed 17 Oct 2018. BNF. BNF Publications; 2018. https://www.bnf.org/. Accessed 17 Oct 2018. Department of Health and Social Care. Drugs and pharmaceutical electronic market information tool (eMIT); 2018. https://www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit. Accessed 17 Oct 2018. Geue C, Lewsey J, Lorgelly P, Govan L, Hart C, Briggs A. Spoilt for choice: implications of using alternative methods of costing hospital episode statistics. Health Econ. 2012;21(10):1201–16. Jones AM. Models for health care. In: Clements M, Hendry D, editors. Handbook of economic forecasting. Oxford: Oxford University Press; 2011. Rouaud M. Probability, statistics and estimation: propagation of uncertainties in experimental measurement; 2017. http://www.incertitudes.fr/book.pdf. Accessed 15 Jan 2018. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ. 2004;13(5):461–75. Mihaylova B, Briggs A, Ohagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897–916. Jones AM, Lomas J, Moore PT, Rice N. A quasi-Monte-Carlo comparison of parametric and semiparametric regression methods for heavy-tailed and non-normal data: an application to healthcare costs. J R Stat Soc Ser A (Stat Soc). 2016;179(4):951–74. Jones AM. Health econometrics. Handbook of health economics. Amsterdam: Elsevier; 2000. p. 265–344. Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non–small cell lung cancer. J Natl Cancer Inst. 2010;102(5):298–306. Cromwell I, van der Hoek K, Taylor SCM, Melosky B, Peacock S. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis. Lung Cancer. 2012;76(3):472–7. Deb P, Manning WG, Norton EC. Modeling health care costs and counts. Annu Rev Public Health. 2014;39:489–505. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004;9(4):197–204. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18(2):153–71. Deb P, Norton EC, Manning WG. Health econometrics using Stata. College Station: Stata Press; 2017. Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics. 2005;6(1):93–109. Holly A, Monfort A, Rockinger M. Fourth order pseudo maximum likelihood methods. J Econom. 2011;162(2):278–93. Jones AM, Lomas J, Rice N. Healthcare cost regressions: going beyond the mean to estimate the full distribution. Health Econ. 2015;24(9):1192–212. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461–94. Gomes M, Grieve R, Nixon R, Edmunds W. Statistical methods for cost-effectiveness analyses that use data from cluster randomized trials: a systematic review and checklist for critical appraisal. Med Decis Mak. 2012;32(1):209–20. Faria R, Hernandez Alava M, Manca A, Wailoo A. NICE DSU Technical Support Document 17: the use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data. Sheffield: University of Sheffield; 2016. Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ. 2008;27(3):531–43. Lewis JA. Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline. Stat Med. 1999;18(15):1903–42. Committee for Medicinal Products for Human Use. Guideline on adjustment for baseline covariates. London: European Medicines Agency; 2015. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14(5):487–96. van Asselt AD, van Mastrigt GA, Dirksen CD, Arntz A, Severens JL, Kessels AG. How to deal with cost differences at baseline. PharmacoEconomics. 2009;27(6):519–28. Little RJ, Rubin DB. Statistical analysis with missing data. New York: Wiley; 2014. Leurent B, Gomes M, Carpenter JR. Missing data in trial-based cost-effectiveness analysis: an incomplete journey. Health Econ. 2018;27(6):1024–40. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing…. presumed at random: cost‐analysis of incomplete data. Health Econ. 2003;12(5):377-92. Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol. 2001;27(1):85–96. Landerman LR, Land KC, Pieper CF. An empirical evaluation of the predictive mean matching method for imputing missing values. Sociol Methods Res. 1997;26(1):3–33. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377–99. Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278–95. Han P. Combining inverse probability weighting and multiple imputation to improve robustness of estimation. Scand J Stat. 2016;43(1):246–60. Galimard JE, Chevret S, Protopopescu C, Resche-Rigon M. A multiple imputation approach for MNAR mechanisms compatible with Heckman’s model. Stat Med. 2016;35(17):2907–20. Heckman JJ. The common structure of statistical models of truncation, sample selection and limited dependent variables and a simple estimator for such models. Ann Econ Soc Meas. 1976;5(4):475–92. Young TA. Estimating mean total costs in the presence of censoring. PharmacoEconomics. 2005;23(12):1229–42. Drummond MF, McGuire A. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press; 2001. Willan AR, Lin D, Manca A. Regression methods for cost-effectiveness analysis with censored data. Stat Med. 2005;24(1):131–45. Wijeysundera HC, Wang X, Tomlinson G, Ko DT, Krahn MD. Techniques for estimating health care costs with censored data: an overview for the health services researcher. ClinicoEcon Outcomes Res. 2012;4:145–55. Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. Sheffield: University of Sheffield; 2011. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Mak. 2012;32(5):722–32. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Chapter 11: Characterizing, reporting, and interpreting uncertainty. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford: Oxford University Press; 2015. p. 389–426. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994;3(2):95–104. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341–64. Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, et al. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technol Assess. 2012;16(46):1–323. Griffin SC, Claxton KP, Palmer SJ, Sculpher MJ. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ. 2011;20(2):212–24. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570–9. Efron B. Nonparametric estimates of standard error: the jackknife, the bootstrap and other methods. Biometrika. 1981;68(3):589–99. Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 2011;20(1):2–15. NICE. Developing NICE guidelines: the manual; 2014. https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview. Accessed 17 Oct 2018. Attema AE, Brouwer WB, Claxton K. Discounting in economic evaluations. PharmacoEconomics. 2018;36(7):745–58. Tinghög G. Discounting, preferences, and paternalism in cost-effectiveness analysis. Health Care Anal. 2012;20(3):297–318. Reinhold T, Brüggenjürgen B, Schlander M, Rosenfeld S, Hessel F, Willich SN. Economic analysis based on multinational studies: methods for adapting findings to national contexts. J Public Health. 2010;18(4):327–35. Oppong R, Jowett S, Roberts TE. Economic evaluation alongside multinational studies: a systematic review of empirical studies. PLoS One. 2015;10(6):e0131949. Vemer P, Rutten-van Mölken MP. The road not taken: transferability issues in multinational trials. PharmacoEconomics. 2013;31(10):863–76. Manca A, Sculpher MJ, Goeree R. The analysis of multinational cost-effectiveness data for reimbursement decisions. PharmacoEconomics. 2010;28(12):1079–96. Briggs A. Transportability of comparative effectiveness and cost-effectiveness between countries. Value Health. 2010;13(Suppl 1):S22–5. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12(4):409–18. Richardson G, Manca A. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Econ. 2004;13(12):1203–10. Hartman E, Grieve R, Ramsahai R, Sekhon JS. From sample average treatment effect to population average treatment effect on the treated: combining experimental with observational studies to estimate population treatment effects. J R Stat Soc Ser A (Stat Soc). 2015;178(3):757–78. Revill P, Walker S, Cambiano V, Phillips A, Sculpher MJ. Reflecting the real value of health care resources in modelling and cost-effectiveness studies: the example of viral load informed differentiated care. PLoS One. 2018;13(1):e0190283. Van Baal P, Morton A, Severens JL. Health care input constraints and cost effectiveness analysis decision rules. Soc Sci Med. 2018;200:59–64.